<DOC>
	<DOCNO>NCT01431950</DOCNO>
	<brief_summary>A randomised , double-blind , multi-centre study evaluate efficacy safety two dos inhale fluticasone furoate treatment persistent asthma adult adolescent currently receive mid high strength inhale corticosteroid .</brief_summary>
	<brief_title>Evaluating Efficacy Safety Fluticasone Furoate Treatment Asthma Adults Adolescents</brief_title>
	<detailed_description>This multi-centre , randomised , double-blind , parallel-group study . Subjects meet inclusion criterion none exclusion criterion Visit 1 ( screen visit ) enter four week Run-In period remain baseline ICS medication . In addition , subject provide albuterol/salbutamol relief asthma symptom . Subjects fail screen eligible re-screening . During Run-In double-blind treatment period subject maintain electronic daily diary record morning even Peak Expiratory Flow ( PEF ) , asthma symptom score rescue albuterol/salbutamol use . Subjects receive contact ( Phone Contact 1/optional office visit ( 1b ) ) Run-In reinforce compliance Run-In medication diary monitoring . Those subject meet eligibility criterion end Run-In period stratify approximately 1:1 ratio accord baseline FEV1 percentage predict normal - one stratum FEV1 percent predict ≥40 % ≤65 % one FEV1 percent predict &gt; 65 % ≤90 % . Once stratify , subject randomise one follow treatment enter 24 week double-blind treatment period:1 ) Fluticasone furoate 100mcg daily even 2 ) Fluticasone furoate 200mcg daily even . Subjects attend 6 on-treatment visit Visits 3 , 4 , 5 , 6 , 7 8 ( Weeks 2 , 4 , 8 , 12 , 18 24 respectively ) . All visit include Visit 1 must conduct even 5 PM 11 PM . Subjects receive treatment 24 week . Twenty four hour urinary cortisol assessment collected end Run-In ( Visit 2 ) end treatment ( Visit 8 ) visit . A follow-up contact perform 1-week completing study medication ( Visit 9 ) . Subjects participate study maximum 29 week ( include screening , treatment follow-up contact ) . In addition , partially use NDPIs collect subset subject . For subject consent pharmacogenetics , blood sample also take pharmacogenetic analysis .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Signed informed consent Outpatient least 12 year age diagnosis asthma least 12 week prior first visit Both gender ; female child bear potential must willing use appropriate contraception Prebronchodilator FEV1 4090 % predict Reversibility FEV1 least 12 % 200mLs Current asthma therapy include inhaled corticosteroid least 4 week prior first visit History life threaten asthma Respiratory infection candidiasis Asthma exacerbation require OCS within last 4 week overnight hospital stay within last 3 month Concurrent respiratory disease disease would confound study participation affect subject safety Allergies study drug , study drug excipients , medication relate study drug Taking another investigational medication medication prohibit use study Previous treatment FF FF/VI phase II III study Night shift worker Children care</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>fluticasone furoate</keyword>
</DOC>